ES2462553A1 - Composition for improvement of sexual well-being (Machine-translation by Google Translate, not legally binding) - Google Patents
Composition for improvement of sexual well-being (Machine-translation by Google Translate, not legally binding) Download PDFInfo
- Publication number
- ES2462553A1 ES2462553A1 ES201430039A ES201430039A ES2462553A1 ES 2462553 A1 ES2462553 A1 ES 2462553A1 ES 201430039 A ES201430039 A ES 201430039A ES 201430039 A ES201430039 A ES 201430039A ES 2462553 A1 ES2462553 A1 ES 2462553A1
- Authority
- ES
- Spain
- Prior art keywords
- page
- composition
- sinensis
- sexual
- documents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 230000001568 sexual effect Effects 0.000 title claims abstract description 39
- 230000036642 wellbeing Effects 0.000 title claims abstract description 22
- 230000006872 improvement Effects 0.000 title claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 26
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 26
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims abstract description 22
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000004475 Arginine Substances 0.000 claims abstract description 16
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 16
- 241000893536 Epimedium Species 0.000 claims abstract description 14
- 240000006079 Schisandra chinensis Species 0.000 claims abstract description 14
- 235000008422 Schisandra chinensis Nutrition 0.000 claims abstract description 14
- 235000018905 epimedium Nutrition 0.000 claims abstract description 14
- 240000004371 Panax ginseng Species 0.000 claims abstract description 13
- 241001521901 Tribulus lanuginosus Species 0.000 claims abstract description 13
- 235000008434 ginseng Nutrition 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960003080 taurine Drugs 0.000 claims abstract description 13
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 13
- 241000382455 Angelica sinensis Species 0.000 claims abstract description 12
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 12
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 12
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 12
- 244000294611 Punica granatum Species 0.000 claims abstract description 12
- 235000014360 Punica granatum Nutrition 0.000 claims abstract description 12
- 244000042430 Rhodiola rosea Species 0.000 claims abstract description 12
- 235000003713 Rhodiola rosea Nutrition 0.000 claims abstract description 12
- 229960003121 arginine Drugs 0.000 claims abstract description 12
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 12
- 241000759833 Cornus officinalis Species 0.000 claims abstract description 11
- 241001632410 Eleutherococcus senticosus Species 0.000 claims abstract description 11
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 11
- 229960001948 caffeine Drugs 0.000 claims abstract description 11
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims abstract description 11
- 241000110637 Cuscuta chinensis Species 0.000 claims abstract description 10
- 229910021538 borax Inorganic materials 0.000 claims abstract description 10
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims abstract description 10
- 239000001095 magnesium carbonate Substances 0.000 claims abstract description 10
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims abstract description 10
- 235000010339 sodium tetraborate Nutrition 0.000 claims abstract description 10
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000011787 zinc oxide Substances 0.000 claims abstract description 10
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 7
- 229960001708 magnesium carbonate Drugs 0.000 claims abstract description 5
- 229960004599 sodium borate Drugs 0.000 claims abstract description 5
- 229960001296 zinc oxide Drugs 0.000 claims abstract description 5
- 241001312519 Trigonella Species 0.000 claims abstract 3
- 201000001881 impotence Diseases 0.000 claims description 33
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 32
- 230000000694 effects Effects 0.000 claims description 16
- 235000009697 arginine Nutrition 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 14
- 239000007910 chewable tablet Substances 0.000 claims description 13
- 229940068682 chewable tablet Drugs 0.000 claims description 12
- 244000250129 Trigonella foenum graecum Species 0.000 claims description 10
- 235000001484 Trigonella foenum graecum Nutrition 0.000 claims description 10
- 239000004615 ingredient Substances 0.000 claims description 10
- 239000003826 tablet Substances 0.000 claims description 10
- 235000001019 trigonella foenum-graecum Nutrition 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 9
- 241000196324 Embryophyta Species 0.000 claims description 8
- 239000011782 vitamin Substances 0.000 claims description 8
- 229940088594 vitamin Drugs 0.000 claims description 8
- 229930003231 vitamin Natural products 0.000 claims description 8
- 235000013343 vitamin Nutrition 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000011677 pyridoxine Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 4
- 235000019158 vitamin B6 Nutrition 0.000 claims description 4
- 235000014692 zinc oxide Nutrition 0.000 claims description 4
- 239000004599 antimicrobial Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000003974 emollient agent Substances 0.000 claims description 3
- 239000003995 emulsifying agent Substances 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 230000003020 moisturizing effect Effects 0.000 claims description 3
- 239000000419 plant extract Substances 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims description 2
- 229930064664 L-arginine Natural products 0.000 claims description 2
- 235000014852 L-arginine Nutrition 0.000 claims description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 235000008160 pyridoxine Nutrition 0.000 claims description 2
- 239000011701 zinc Substances 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- 241000125175 Angelica Species 0.000 claims 2
- 235000001287 Guettarda speciosa Nutrition 0.000 claims 2
- 230000005184 men's health Effects 0.000 claims 2
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 1
- 235000003392 Curcuma domestica Nutrition 0.000 claims 1
- 241000207901 Cuscuta Species 0.000 claims 1
- 241000490050 Eleutherococcus Species 0.000 claims 1
- -1 L-arginine (page 2 Chemical class 0.000 claims 1
- 235000015468 Lycium chinense Nutrition 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 229910052796 boron Inorganic materials 0.000 claims 1
- 102220240796 rs553605556 Human genes 0.000 claims 1
- 235000013976 turmeric Nutrition 0.000 claims 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical class O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 19
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 18
- 210000003899 penis Anatomy 0.000 description 10
- 229960003604 testosterone Drugs 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 101000988412 Homo sapiens cGMP-specific 3',5'-cyclic phosphodiesterase Proteins 0.000 description 6
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 5
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 5
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 5
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000035946 sexual desire Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 4
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 4
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 4
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 3
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 3
- 201000001880 Sexual dysfunction Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- MYCMTMIGRXJNSO-UHFFFAOYSA-N moxaverine Chemical compound N=1C(CC)=CC2=CC(OC)=C(OC)C=C2C=1CC1=CC=CC=C1 MYCMTMIGRXJNSO-UHFFFAOYSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 231100000872 sexual dysfunction Toxicity 0.000 description 3
- 230000036332 sexual response Effects 0.000 description 3
- 229960003310 sildenafil Drugs 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 230000024883 vasodilation Effects 0.000 description 3
- REZGGXNDEMKIQB-UHFFFAOYSA-N zaprinast Chemical compound CCCOC1=CC=CC=C1C1=NC(=O)C2=NNNC2=N1 REZGGXNDEMKIQB-UHFFFAOYSA-N 0.000 description 3
- 229950005371 zaprinast Drugs 0.000 description 3
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010057671 Female sexual dysfunction Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 239000000006 Nitroglycerin Substances 0.000 description 2
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 2
- 208000012931 Urologic disease Diseases 0.000 description 2
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 229920002770 condensed tannin Polymers 0.000 description 2
- 210000005226 corpus cavernosum Anatomy 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000001856 erectile effect Effects 0.000 description 2
- 230000002270 ergogenic effect Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229960003711 glyceryl trinitrate Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 2
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960002902 moxaverine Drugs 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229960001789 papaverine Drugs 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 2
- 229960004380 tramadol Drugs 0.000 description 2
- 208000014001 urinary system disease Diseases 0.000 description 2
- 229960002381 vardenafil Drugs 0.000 description 2
- SUUWYOYAXFUOLX-ZBRNBAAYSA-N (2s)-2-aminobutanedioic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@@H](N)CCCN=C(N)N SUUWYOYAXFUOLX-ZBRNBAAYSA-N 0.000 description 1
- IKQCSJBQLWJEPU-UHFFFAOYSA-N 2,5-dihydroxybenzenesulfonic acid Chemical class OC1=CC=C(O)C(S(O)(=O)=O)=C1 IKQCSJBQLWJEPU-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010078321 Guanylate Cyclase Proteins 0.000 description 1
- 102000014469 Guanylate cyclase Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241000238866 Latrodectus mactans Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 206010051482 Prostatomegaly Diseases 0.000 description 1
- 240000009089 Quercus robur Species 0.000 description 1
- 235000011471 Quercus robur Nutrition 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000002160 alpha blocker Substances 0.000 description 1
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- HSNWZBCBUUSSQD-UHFFFAOYSA-N amyl nitrate Chemical compound CCCCCO[N+]([O-])=O HSNWZBCBUUSSQD-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229960004046 apomorphine Drugs 0.000 description 1
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 229960002223 arginine aspartate Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000003222 cGMP degradation Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- BGOFCVIGEYGEOF-UJPOAAIJSA-N helicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1C=O BGOFCVIGEYGEOF-UJPOAAIJSA-N 0.000 description 1
- 229940068628 helicin Drugs 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 229940093221 imdur Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229940093268 isordil Drugs 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004995 male reproductive system Anatomy 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003170 musculotropic effect Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 229940072991 nitro-bid Drugs 0.000 description 1
- 229960002460 nitroprusside Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 201000011264 priapism Diseases 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- BGOFCVIGEYGEOF-UHFFFAOYSA-N salicylaldehyde beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1C=O BGOFCVIGEYGEOF-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 229960002639 sildenafil citrate Drugs 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- 231100000398 testicular damage Toxicity 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940125725 tranquilizer Drugs 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 229940047183 tribulus Drugs 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 229940094720 viagra Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A61K9/0058—Chewing gums
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Composición para mejora del bienestar sexual Composition to improve sexual well-being
La presente invención se enmarca dentro del campo farmacéutico y alimenticio, concretamente en el campo de la mejora de la capacidad y bienestar sexual de ambos sexos, de la actividad sexual masculina, el tratamiento de la disfunción sexual y la salud del sistema vascular sexual de ambos sexos. The present invention is framed within the pharmaceutical and nutritional field, specifically in the field of the improvement of sexual capacity and well-being of both sexes, of male sexual activity, the treatment of sexual dysfunction and the health of the sexual vascular system of both sexes
Concretamente la presente invención se refiere a una composición oral formulada como comprimidos, granulados y soluciones, entre otros, que comprende una mezcla de extractos de origen natural y otros ingredientes alimenticios. La presente invención también se refiere al uso de la misma para la preparación de un medicamento para tratamiento de la disfunción eréctil y la disfunción sexual femenina. Specifically, the present invention relates to an oral composition formulated as tablets, granules and solutions, among others, comprising a mixture of extracts of natural origin and other food ingredients. The present invention also relates to the use thereof for the preparation of a medicament for the treatment of erectile dysfunction and female sexual dysfunction.
La disfunción eréctil (DE) es una enfermedad frecuente que afecta a muchos hombres. Puede que empiece en las relaciones de pareja, pero también puede interferir en muchos otros aspectos de la vida, por ejemplo en la autoestima. La definición técnica de DE es la incapacidad de lograr o mantener una erección suficiente como para tener una relación sexual satisfactoria (Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54-61). Erectile dysfunction (ED) is a common disease that affects many men. It may start in relationships, but it can also interfere in many other aspects of life, for example in self-esteem. The technical definition of ED is the inability to achieve or maintain an erection sufficient to have a satisfactory sexual relationship (Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994; 151: 54-61).
La erección es un proceso complejo que requiere cambios en los músculos, los nervios y los vasos sanguíneos del pene. Pero para simplificar, la DE aparece cuando la sangre no puede entrar o permanecer en cantidad suficiente en el pene y durante el tiempo suficiente para mantener la erección (National Kidney and Urologic Diseases Information Clearinghouse. Erectile Dysfunction. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health; 2009). Erection is a complex process that requires changes in the muscles, nerves and blood vessels of the penis. But to simplify, ED appears when blood cannot enter or remain in sufficient quantity in the penis and for long enough to maintain an erection (National Kidney and Urologic Diseases Information Clearinghouse. Erectile Dysfunction. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health; 2009).
El proceso de erección exige una secuencia de acontecimientos y la DE puede suceder cuando se interrumpe cualquiera de ellos. Los eventos necesarios incluyen impulsos nerviosos en el cerebro, la médula espinal y la zona que rodea el pene, así como diversas respuestas en los músculos, tejidos fibrosos, venas y arterias del cuerpo cavernoso y cercanas. The erection process requires a sequence of events and ED can happen when any of them is interrupted. The necessary events include nerve impulses in the brain, spinal cord and the area surrounding the penis, as well as various responses in the muscles, fibrous tissues, veins and arteries of the cavernous and nearby body.
En ocasiones la disfunción eréctil está asociada a diferentes enfermedades, como la diabetes, renopatía, alcoholismo crónico, esclerosis múltiple, arteriosclerosis, enfermedad vascular o enfermedad neurológica, pero también puede ser un efecto secundario de la medicación (p. ej., un efecto secundario de un antihipertensivo, antihistamínico, antidepresivo, tranquilizante, supresor del apetito entre otros). Otras causas incluyen los traumatismos, incluyendo la cirugía (en particular, cirugía prostática) que provoca daños nerviosos o limita el flujo sanguíneo en el pene. En ausencia de cualquier causa orgánica, se puede determinar que la DE tiene un origen psicológico (DEP), como la depresión, la ansiedad, el estrés, la tensión o la culpabilidad. La DE no es una consecuencia normal del envejecimiento, pero su incidencia aumenta con la edad. Sometimes erectile dysfunction is associated with different diseases, such as diabetes, renopathy, chronic alcoholism, multiple sclerosis, arteriosclerosis, vascular disease or neurological disease, but it can also be a side effect of the medication (e.g., a side effect of an antihypertensive, antihistamine, antidepressant, tranquilizer, appetite suppressant among others). Other causes include trauma, including surgery (particularly prostate surgery) that causes nerve damage or limits blood flow in the penis. In the absence of any organic cause, it can be determined that ED has a psychological origin (DEP), such as depression, anxiety, stress, tension or guilt. ED is not a normal consequence of aging, but its incidence increases with age.
Cerca del 52% de los hombres de entre 40 y 70 años tiene DE (National Kidney and Urologic Diseases Information Clearinghouse. Erectile Dysfunction. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health; 2009). About 52% of men in their 40s and 70s have ED (National Kidney and Urologic Diseases Information Clearinghouse. Erectile Dysfunction. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health; 2009).
Los tratamientos farmacológicos estándar para la DE incluyen una clase de fármacos conocidos como inhibidores de la fosfodiesterasa tipo 5 (PDE-5), como el citrato de sildenafilo (Viagra®). A pesar de que estos fármacos pueden ser muy efectivos, alrededor del 30% del total de los pacientes tratados sufren efectos secundarios. Los inhibidores de PDE-5 están asociados con efectos secundarios que incluyen cefalea, enrojecimiento del rostro, molestias estomacales, congestión nasal, infección del tracto urinario, cambios visuales, como cambios leves y temporales en los colores azul/verde o aumento de la sensibilidad a la luz y diarrea. Por otra parte, estos fármacos están contraindicados en pacientes que están tomando fármacos a base de nitratos para la angina de pecho, como nitroglicerina (Nitro-Bid™, entre otros), mononitrato de isosorbida (Imdur™) y dinitrato de isosorbida (Isordil™); anticoagulantes y determinados Standard pharmacological treatments for ED include a class of drugs known as phosphodiesterase type 5 (PDE-5) inhibitors, such as sildenafil citrate (Viagra®). Although these drugs can be very effective, about 30% of the total treated patients suffer from side effects. PDE-5 inhibitors are associated with side effects that include headache, redness of the face, stomach discomfort, nasal congestion, urinary tract infection, visual changes, such as mild and temporary changes in blue / green colors or increased sensitivity to Light and diarrhea. On the other hand, these drugs are contraindicated in patients who are taking nitrate-based drugs for angina pectoris, such as nitroglycerin (Nitro-Bid ™, among others), isosorbide mononitrate (Imdur ™) and isosorbide dinitrate (Isordil ™ ); anticoagulants and certain
tipos de bloqueadores alfa para la próstata agrandada (hiperplasia prostática benigna) o tensión arterial elevada. types of alpha blockers for enlarged prostate (benign prostatic hyperplasia) or high blood pressure.
Además, los inhibidores de PDE-5 pueden no ser adecuados para los pacientes que sufren una cardiopatía grave, fallo cardíaco, hipotensión, hipertensión, diabetes incontrolada o que han sufrido un accidente cerebro vascular, así como para los pacientes con trastornos hematológicos que pueden estar asociados con el priapismo (por ejemplo, anemia de células falciformes, mieloma múltiple o leucemia). In addition, PDE-5 inhibitors may not be suitable for patients suffering from severe heart disease, heart failure, hypotension, hypertension, uncontrolled diabetes or who have suffered a stroke, as well as for patients with hematologic disorders that may be associated with priapism (for example, sickle cell anemia, multiple myeloma or leukemia).
Por consiguiente, existe una constante necesidad de terapias seguras y efectivas para el tratamiento de la DE. Así como de una composición que sea también efectiva para mujeres, en particular para el tratamiento de la disfunción sexual femenina. Therefore, there is a constant need for safe and effective therapies for the treatment of ED. As well as a composition that is also effective for women, in particular for the treatment of female sexual dysfunction.
Existen diferentes documentos del estado de la técnica que se refieren a patentes dirigidas a formulaciones para mejora del bienestar sexual. Entre estos documentos encontramos la solicitud de patente WO2011161655, relativa a una formulación para mejorar la condición física o el bienestar sexual de mujeres y hombres, para realzar el vigor masculino, y para el tratamiento de la disfunción sexual y la salud del sistema vascular sexual de ambos sexos con ingredientes que incluyen una fuente de proantocianidinas, una fuente de arginina, extracto de rosa mosqueta y / o extracto de Quercus robur. La fuente de proantocianidinas puede ser un extracto vegetal y la fuente de la arginina puede ser aspartato de arginina. There are different state-of-the-art documents that refer to patents aimed at formulations to improve sexual well-being. Among these documents are patent application WO2011161655, concerning a formulation to improve the physical condition or sexual well-being of women and men, to enhance male vigor, and for the treatment of sexual dysfunction and the health of the sexual vascular system of both sexes with ingredients that include a source of proanthocyanidins, a source of arginine, rosehip extract and / or Quercus robur extract. The source of proanthocyanidins can be a plant extract and the source of arginine can be arginine aspartate.
También encontramos el documento de solicitud de patente WO2013093096, que se refiere a composiciones pueden aumentar el bienestar sexual de hombres sanos y mujeres sanos. La ingestión de la composición objeto de esta solicitud proporciona mejora en los resultados de la función sexual tanto en hombres como en mujeres, mejorando el deseo sexual, la excitación sexual y la respuesta sexual tanto en hombres sanos y mujeres sanos. We also found patent application document WO2013093096, which refers to compositions that can increase the sexual well-being of healthy men and healthy women. Ingestion of the composition object of this application provides improvement in the results of sexual function in both men and women, improving sexual desire, sexual arousal and sexual response in both healthy men and healthy women.
Sin embargo, la mayoría del estado de la técnica se centra en numerosas patentes relativas a diferentes fórmulas farmacéuticas para tratamiento de la disfunción eréctil (DE). However, most of the state of the art focuses on numerous patents relating to different pharmaceutical formulas for the treatment of erectile dysfunction (ED).
Así, tenemos por ejemplo la patente internacional WO2009083808 se refiere a polipéptidos activos desde un punto de vista terapéutico y originalmente obtenidos de la araña chilena Latrodectus mactans, así como métodos para su purificación y uso en el tratamiento de la disfunción eréctil (DE). Por otro lado, la patente internacional WO2008100926 se refiere al tratamiento de la eyaculación precoz y la disfunción eréctil co-mórbidas en un hombre, que comprende administrar un material de tramadol como un inhibidor de fosfodiesterasa al hombre. La invención se refiere específicamente a una composición farmacéutica que comprende un material de tramadol y un inhibidor de fosfodiesterasa. Thus, we have for example the international patent WO2009083808 refers to polypeptides active from a therapeutic point of view and originally obtained from the Chilean spider Latrodectus mactans, as well as methods for their purification and use in the treatment of erectile dysfunction (ED). On the other hand, the international patent WO2008100926 refers to the treatment of premature ejaculation and co-morbid erectile dysfunction in a man, which comprises administering a tramadol material as a phosphodiesterase inhibitor to man. The invention specifically relates to a pharmaceutical composition comprising a tramadol material and a phosphodiesterase inhibitor.
Por otro lado, la patente internacional WO2009121687 se refiere a L-citrulina a una dosis igual a 6 g/día y su composición farmacéutica para tratar la disfunción eréctil. On the other hand, the international patent WO2009121687 refers to L-citrulline at a dose equal to 6 g / day and its pharmaceutical composition for treating erectile dysfunction.
La patente europea EP1315502 se refiere al uso de un gel hidroalcohólico que comprende un esteroide en la ruta sintética de la testosterona, uno o más alcoholes C1-C4, un agente potenciador de la penetración, un espesante y agua, para la fabricación de un medicamento para mejorar la eficacia de un producto farmacéutico útil para tratar la disfunción eréctil en un sujeto masculino, en el que el medicamento se administra por vía percutánea a un sujeto, en el que el producto farmacéutico es un inhibidor de fosfodiesterasa tipo 5. European patent EP1315502 refers to the use of a hydroalcoholic gel comprising a steroid in the synthetic route of testosterone, one or more C1-C4 alcohols, a penetration enhancing agent, a thickener and water, for the manufacture of a medicament. to improve the efficacy of a pharmaceutical product useful for treating erectile dysfunction in a male subject, in which the medication is administered percutaneously to a subject, in which the pharmaceutical product is a phosphodiesterase type 5 inhibitor.
La patente española ES2318023 se refiere a al empleo de derivados de ácidos 2,5-dihidroxibencenosulfónicos de fórmula general (I), en la elaboración de medicamentos útiles en terapéutica para potenciar los efectos de los inhibidores de la fosfodiesterasa-5 incluyendo sildenafilo, vardenafilo y IC-351, de apomorfina, de los donadores de óxido nítrico incluyendo nitrato de amilo, nitroglicerina, nitroprusiato, nitrosotioles y nicorandilo, de los compuestos que aumentan el nivel de GMP cíclico en el tejido peneano y de otros compuestos destinados a promover la erección del pene en el hombre. The Spanish patent ES2318023 refers to the use of derivatives of 2,5-dihydroxybenzenesulfonic acids of general formula (I), in the elaboration of drugs useful in therapeutics to enhance the effects of phosphodiesterase-5 inhibitors including sildenafil, vardenafil and IC-351, of apomorphine, of nitric oxide donors including amyl nitrate, nitroglycerin, nitroprusside, nitrosothiols and nicorandyl, of compounds that increase the level of cyclic GMP in penile tissue and other compounds intended to promote erection of penis in man.
La patente europea EP1458389 se refiere a una formulación acuosa de moxaverina, así como a la utilización de moxaverina para la preparación de medicamentos. Moxaverina es un desarrollo perfeccionado del principio activo papaverina y actúa como espasmolítico musculotrópico, el cual es 2,5 veces más eficaz que la sustancia madre papaverina. European patent EP1458389 refers to an aqueous formulation of moxaverine, as well as the use of moxaverine for the preparation of medicaments. Moxaverina is an improved development of the active substance papaverine and acts as a musculotropic spasmolytic, which is 2.5 times more effective than the mother substance papaverine.
Sin embargo ninguna de las composiciones anteriormente citadas se refiere a una composición de productos naturales 100%, que se muestra eficaz y segura para tratar la disfunción eréctil ni para el bienestar de ambos sexos. However, none of the aforementioned compositions refers to a 100% natural product composition, which is shown to be effective and safe for treating erectile dysfunction or for the well-being of both sexes.
El objetivo de la presente invención es la obtención de una composición administrada por vía oral con acción farmacológica y nutricional para la mejora del bienestar sexual de personas de ambos sexos. En particular la invención se refiere a una composición para mejorar la capacidad y bienestar sexual de personas de ambos sexos, en particular para la mejora de la actividad sexual masculina, para el tratamiento de la disfunción sexual y la salud del sistema vascular sexual de ambos sexos. La presente composición es capaz de aumentar el bienestar sexual de hombres y mujeres sanos. La ingestión por vía oral de la presente composición mejora la excitación sexual y la respuesta sexual tanto en hombres sanos y mujeres sanos, dando como resultado un mayor bienestar sexual. The objective of the present invention is to obtain a composition administered orally with pharmacological and nutritional action to improve the sexual well-being of people of both sexes. In particular, the invention relates to a composition for improving the sexual capacity and well-being of people of both sexes, in particular for the improvement of male sexual activity, for the treatment of sexual dysfunction and the health of the sexual vascular system of both sexes. . The present composition is capable of increasing the sexual well-being of healthy men and women. Oral ingestion of the present composition improves sexual arousal and sexual response in both healthy men and healthy women, resulting in greater sexual well-being.
La composición de la presente invención es una composición farmacéutica y alimenticia en forma de comprimido masticable, u otras formas de administración oral, para tratamiento de la disfunción eréctil que comprende una cantidad efectiva de Angelica sinensis, Cornus officinalis, Curcuma longa, Epimedium, Lycium barbarum, Punica granatum, The composition of the present invention is a pharmaceutical and food composition in the form of a chewable tablet, or other forms of oral administration, for the treatment of erectile dysfunction comprising an effective amount of Angelica sinensis, Cornus officinalis, Curcuma longa, Epimedium, Lycium barbarum , Punica granatum,
Schisandra chinensis, Trigonella foenum-graecum, Tribulus terrestris, Rhodiola rosea, Eleutherococcus senticosus, Panax ginseng, Cuscuta sinensis, Arginina, Cafeína, Carbonato de magnesio, Taurina, Oxido de zinc, Vitamina B6 y Borato sódico. Schisandra chinensis, Trigonella foenum-graecum, Tribulus terrestris, Rhodiola rosea, Eleutherococcus senticosus, Panax ginseng, Cuscuta sinensis, Arginine, Caffeine, Magnesium carbonate, Taurine, Zinc oxide, Vitamin B6 and Sodium borate.
Los ingredientes activos que componen la formulación objeto de la presente invención, tienen las siguientes propiedades, considerando cinco grupos de ingredientes con acciones complementarias y sinérgicas para atender a las necesidades masculinas: The active ingredients that make up the formulation object of the present invention have the following properties, considering five groups of ingredients with complementary and synergistic actions to meet the male needs:
Plantas vigorizantes sexuales: -Angelica sinensis: liberación de óxido nítrico con la consiguiente relajación de la musculatura lisa del cuerpo Sexual invigorating plants: -Angelica sinensis: release of nitric oxide with the consequent relaxation of the smooth muscles of the body
cavernoso. -Cornus officinalis: incrementa la presión del cuerpo cavernoso mejorando la erección. -Curcuma longa: mejora de la erección elevando el c-GMP. -Cuscuta sinensis: estimula la secreción de testosterona. -Epimedium: inhibe la PED-5 y aumenta la producción de NO, conllevando a una mayor producción de testosterona cavernous. -Cornus officinalis: increases the pressure of the cavernous body improving erection. -Curcuma longa: improvement of the erection by raising the c-GMP. -Cuscuta sinensis: stimulates the secretion of testosterone. -Epimedium: inhibits PED-5 and increases NO production, leading to increased testosterone production
y a una mejora de la erección. -Lycium barbarum: acción antioxidante que protege frente al daño testicular. -Punica granatum: aumenta los niveles de testosterona, mejora la erección via la producción de NO y posee acción and to an erection improvement. -Lycium barbarum: antioxidant action that protects against testicular damage. -Punica granatum: increases testosterone levels, improves erection via NO production and has action
antioxidante. -Schisandra chinensis: actúa a nivel de contractilidad de la musculatura lisa del corpus cavernoso y el metabolismo antioxidant -Schisandra chinensis: acts at the level of contractility of the smooth musculature of the corpora cavernosa and metabolism
del calcio, mejorando la erección. -Trigonella foenum-graecum: mantenimiento de los niveles de testosterona y aumento del deseo sexual y la libido. -Tribulus terrestris: aumento de los niveles de testosterona e incremento del deseo sexual. of calcium, improving erection. -Trigonella foenum-graecum: maintenance of testosterone levels and increased sexual desire and libido. -Tribulus terrestris: increased testosterone levels and increased sexual desire.
Plantas energizantes-adaptógenas. Poseen acción ergogénica, potenciando la predisposición, el deseo y la potencia sexual: Energizing-adaptogenic plants. They have ergogenic action, promoting predisposition, desire and sexual potency:
- --
- Rhodiola rosea -Eleutherococcus senticosus -Panax ginseng Rhodiola rosea -Eleutherococcus senticosus -Panax ginseng
Elementos fortificantes y estimulantes. Sustancias de efecto ergogénico y cognitivo, resultando un incremento de la potencia sexual: Fortifying and stimulating elements. Substances with an ergogenic and cognitive effect, resulting in an increase in sexual potency:
- --
- cafeína -taurina caffeine-taurine
Aminoácidos activos: Active amino acids:
- --
- Arginina: la L-Arginina es un aminoácido semi-esencial, es decir, el organismo lo sintetiza en cantidad adecuada, pero hay determinadas situaciones en las que sus necesidades son mayores y hay que suplementarlo. Interviene en la primera fase de la respuesta erectiva. Por acción de la enzima óxido-sintetasa, se convierte en óxido nítrico (gas vasodilatador) que produce el comienzo del proceso de vasodilatación en los cuerpos cavernosos del pene aumentando la capacidad eréctil. Estudios iniciales en el estado del arte proponen que los hombres con bajos niveles de nitrato en sangre o en orina pueden hallar que los suplementos de arginina son útiles para el manejo de la disfunción eréctil. Arginine: L-Arginine is a semi-essential amino acid, that is, the body synthesizes it in adequate quantity, but there are certain situations in which its needs are greater and must be supplemented. It intervenes in the first phase of the erectile response. By the action of the enzyme oxide synthetase, it is converted into nitric oxide (vasodilator gas) that produces the beginning of the vasodilation process in the cavernous bodies of the penis, increasing the erectile capacity. Initial studies in the state of the art propose that men with low levels of nitrate in blood or urine may find that arginine supplements are useful for the management of erectile dysfunction.
Minerales y vitaminas: -Zinc: mineral esencial para el sistema reproductor masculino, ya que está implicado en el crecimiento y desarrollo de los órganos sexuales, la cantidad y movilidad de los espermatozoides y los niveles de testosterona -Magnesio: aumenta los niveles de testosterona libre, aumenta la concentración de óxido nítrico y disminuye los Minerals and vitamins: -Zinc: essential mineral for the male reproductive system, since it is involved in the growth and development of sexual organs, the amount and mobility of sperm and testosterone levels -Magnesium: increases free testosterone levels , increases the concentration of nitric oxide and decreases the
niveles de calcio intracelular, con la consiguiente mejora de la respuesta sexual. -Boro: aumenta los niveles de testosterona. -Vitamina B6 (piridoxina): incrementa la absorción de magnesio intracellular calcium levels, with the consequent improvement of the sexual response. -Boro: increases testosterone levels. -Vitamin B6 (pyridoxine): increases magnesium absorption
La composición de la siguiente invención comprende al menos los siguientes ingredientes en los siguientes intervalos de cantidad, expresada en milígramos (mg): La formulación objeto de la presente invención se administra por vía oral (por ejemplo en forma de comprimidos, granulados, soluciones, etc.). De forma preferida es en forma de comprimido masticable de 2500 mg cada comprimido. De forma preferida, la posología adecuada de la presente formulación es de dos comprimidos al menos tres horas antes de comenzar la actividad. De forma preferida se deben tomar fuera de las comidas para mejorar los resultados. The composition of the following invention comprises at least the following ingredients in the following quantity ranges, expressed in milligrams (mg): The formulation object of the present invention is administered orally (for example in the form of tablets, granules, solutions, etc.). Preferably, it is in the form of a chewable tablet of 2500 mg each tablet. Preferably, the appropriate dosage of the present formulation is two tablets at least three hours before starting the activity. Preferably, they should be taken outside of meals to improve results.
- Ingredientes Ingredients
- mg mg
- Tribulus terrestris Tribulus Terrestris
- 250-750 mg 250-750 mg
- Arginina Arginine
- 125- 1000 mg 125-1000 mg
- Taurina Taurine
- 125- 1000 mg 125-1000 mg
- Trigonella foenum-graecum Trigonella foenum-graecum
- 75-300 mg 75-300 mg
- Epimedium Epimedium
- 75-205 mg 75-205 mg
- Carbonato de magnesio Magnesium carbonate
- 100- 200 mg 100-200 mg
- Schisandra sinensis Schisandra sinensis
- 50- 150 mg 50-150 mg
- Angelica sinensis Angelica sinensis
- 50-100 mg 50-100 mg
- Lycium barbarum Lycium barbarum
- 30-500 mg 30-500 mg
- Cuscuta sinensisCuscuta sinensis
- 25-200 mg 25-200 mg
- Punica granatum Punica granatum
- 25-500 mg 25-500 mg
- Rhodiola rosea Rhodiola rosea
- 25-500 mg 25-500 mg
- Eleutherococcus senticosus Eleutherococcus senticosus
- 25-500 mg 25-500 mg
- Panax ginseng Panax ginseng
- 25-500 mg 25-500 mg
- Borato sódico Sodium borate
- 25-50 mg 25-50 mg
- Curcuma longa Curcuma longa
- 20-100 mg 20-100 mg
- Cornus officinalis Cornus officinalis
- 10-40 mg 10-40 mg
- Cafeína Caffeine
- 10-300mg 10-300mg
- Oxido de Zinc Zinc oxide
- 5-13 mg 5-13 mg
- Vitamina B6-piridoxina Vitamin B6-Pyridoxine
- 3-6 mg 3-6 mg
Según otro aspecto, la composición objeto de la presente invención adicionalmente comprende excipientes, tales como agentes hidratantes, agentes antioxidantes, agentes emulgentes, agentes estabilizantes, agentes emolientes y agentes antimicrobianos. According to another aspect, the composition object of the present invention additionally comprises excipients, such as moisturizing agents, antioxidant agents, emulsifying agents, stabilizing agents, emollient agents and antimicrobial agents.
Según otro aspecto la composición está formulada como comprimido masticable. According to another aspect, the composition is formulated as a chewable tablet.
Una composición preferida de la siguiente invención comprende al menos los siguientes elementos en las siguientes cantidades: A preferred composition of the following invention comprises at least the following elements in the following amounts:
- Ingredientes Ingredients
- mg/composición mg / composition
- Tribulus terrestris Tribulus Terrestris
- 500 mg 500 mg
- Arginina Arginine
- 250,00 mg 250.00 mg
- Taurina Taurine
- 250,00 mg 250.00 mg
- Trigonella foenum-graecum Trigonella foenum-graecum
- 150,00 mg 150.00 mg
- Epimedium Epimedium
- 125,00 mg 125.00 mg
- Carbonato de magnesio Magnesium carbonate
- 125,00 mg 125.00 mg
- Schisandra sinensis Schisandra sinensis
- 100,00 mg 100.00 mg
- Angelica sinensis Angelica sinensis
- 75,00 mg 75.00 mg
- Lycium barbarum Lycium barbarum
- 60,00 mg 60.00 mg
- Cuscuta sinensis Cuscuta sinensis
- 50,00 mg 50.00 mg
- Punica granatum Punica granatum
- 50,00 mg 50.00 mg
- Rhodiola rosea Rhodiola rosea
- 50,00 mg 50.00 mg
- Eleutherococcus senticosus Eleutherococcus senticosus
- 50,00 mg 50.00 mg
- Panax ginseng Panax ginseng
- 50,00 mg 50.00 mg
- Borato sódico Sodium borate
- 44,10 mg 44.10 mg
- Curcuma longa Curcuma longa
- 32,50 mg 32.50 mg
- Cornus officinalis Cornus officinalis
- 20,00 mg 20.00 mg
- Cafeína Caffeine
- 15,00 mg 15.00 mg
- Oxido de zinc Zinc oxide
- 6,25 mg 6.25 mg
- Vitamina B6-piridoxina Vitamin B6-Pyridoxine
- 3,00 mg 3.00 mg
- Excipientes Excipients
- 491,15 mg 491.15 mg
De acuerdo con otro aspecto la presente invención se refiere al uso de la composición anteriormente citada para la preparación de un medicamento para aumentar el bienestar sexual de hombres y mujeres sanos. According to another aspect, the present invention relates to the use of the aforementioned composition for the preparation of a medicament to increase the sexual well-being of healthy men and women.
De acuerdo con otro aspecto la presente invención se refiere al uso de la composición anteriormente citada para la preparación de un medicamento para el tratamiento de la disfunción eréctil. In accordance with another aspect the present invention relates to the use of the aforementioned composition for the preparation of a medicament for the treatment of erectile dysfunction.
De acuerdo con otro aspecto la presente invención se refiere al uso de la composición anteriormente citada para la preparación de un medicamento en forma de comprimido masticable. De forma preferida el medicamento está en forma de comprimido masticable de 2500 mg. In accordance with another aspect the present invention relates to the use of the aforementioned composition for the preparation of a medicament in the form of a chewable tablet. Preferably, the medicament is in the form of a chewable tablet of 2500 mg.
De acuerdo con otro aspecto la presente invención se refiere al uso de la composición anteriormente citada para la preparación de un medicamento administrado en pautas de posología de dos comprimidos por vía oral al menos tres horas antes del acto sexual. According to another aspect, the present invention relates to the use of the aforementioned composition for the preparation of a medicament administered in dosing guidelines of two tablets orally at least three hours before sexual intercourse.
EJEMPLOS DE REALIZACIÓN: EXAMPLES OF REALIZATION:
Los siguientes ejemplos específicos que se proporcionan aquí sirven para ilustrar la naturaleza de la presente invención. Estos ejemplos se incluyen solamente con fines ilustrativos y no han de ser interpretados como limitaciones a la invención que aquí se reivindica. The following specific examples provided herein serve to illustrate the nature of the present invention. These examples are included for illustrative purposes only and should not be construed as limitations on the invention claimed herein.
Ejemplo 1: Evaluación de la actividad farmacológica para hombres y mujeres Example 1: Evaluation of pharmacological activity for men and women
Mediante un proceso de mezclado, estabilización y compresión se obtiene el comprimido masticable objeto de la presente invención. The chewable tablet object of the present invention is obtained by means of a mixing, stabilization and compression process.
Este comprimido comprende los siguientes elementos: Esta composición se administró tres horas antes del acto sexual, tomando dos comprimidos masticables en una población de 10 varones y 10 mujeres. Al cabo de un mes se les facilitó una encuesta para valorar la actividad y satisfacción con el producto y se apreció satisfactoriamente que los resultados fueron claramente positivos en un 100% de los pacientes encuestados. This tablet comprises the following elements: This composition was administered three hours before sexual intercourse, taking two chewable tablets in a population of 10 men and 10 women. After a month they were given a survey to assess the activity and satisfaction with the product and it was satisfactorily appreciated that the results were clearly positive in 100% of the patients surveyed.
- Ingredientes Ingredients
- mg/composición mg / composition
- Tribulus terrestris Tribulus Terrestris
- 500 mg 500 mg
- Arginina Arginine
- 250,00 mg 250.00 mg
- Taurina Taurine
- 250,00 mg 250.00 mg
- Trigonella foenum-graecum Trigonella foenum-graecum
- 150,00 mg 150.00 mg
- Epimedium Epimedium
- 125,00 mg 125.00 mg
- Carbonato de magnesio Magnesium carbonate
- 125,00 mg 125.00 mg
- Schisandra sinensis Schisandra sinensis
- 100,00 mg 100.00 mg
- Angelica sinensis Angelica sinensis
- 75,00 mg 75.00 mg
- Lycium barbarum Lycium barbarum
- 60,00 mg 60.00 mg
- Cuscuta sinensis Cuscuta sinensis
- 50,00 mg 50.00 mg
- Punica granatum Punica granatum
- 50,00 mg 50.00 mg
- Rhodiola rosea Rhodiola rosea
- 50,00 mg 50.00 mg
- Eleutherococcus senticosus Eleutherococcus senticosus
- 50,00 mg 50.00 mg
- Panax ginseng Panax ginseng
- 50,00 mg 50.00 mg
- Borato sódico Sodium borate
- 44,10 mg 44.10 mg
- Curcuma longa Curcuma longa
- 32,50 mg 32.50 mg
- Cornus officinalis Cornus officinalis
- 20,00 mg 20.00 mg
- Cafeína Caffeine
- 15,00 mg 15.00 mg
- Oxido de zinc Zinc oxide
- 6,25 mg 6.25 mg
- Vitamina B6-piridoxina Vitamin B6-Pyridoxine
- 3,00 mg 3.00 mg
- Excipientes Excipients
- 491,15 mg 491.15 mg
Los parámetros más positivamente aceptados por los pacientes fueron: The most positively accepted parameters by the patients were:
- --
- Vitalidad masculina: bienestar de la fisiología masculina para el adecuado funcionamiento a nivel sexual. -Actividad energizante: aumenta la resistencia y potencia masculina, el deseo sexual y la claridad mental. -Factor psicológico: mejora la superación de situaciones de estrés y desgano físico, específicamente en el plano Male vitality: well-being of male physiology for proper functioning at the sexual level. -Energizing activity: increases male endurance and potency, sexual desire and mental clarity. - Psychological factor: improves the overcoming of situations of stress and physical reluctance, specifically in the plane
sexual. -Calidad de la función sexual. -Aumento del deseo sexual en mujeres. sexual. -Quality of sexual function. -Increase of sexual desire in women.
Ejemplo 2: Actividad Biológica sobre la inhibición de la enzima PDE5A Example 2: Biological Activity on the inhibition of the PDE5A enzyme
Parte del proceso fisiológico de la erección incluye al sistema nervioso parasimpático causando la liberación de óxido nítrico (NO) en el cuerpo cavernoso del pene. El NO se une a los receptores de la enzima guanilato ciclasa, lo que deriva en niveles aumentados de guanosín monofosfato cíclico (GMPc), llevando a una relajación del músculo liso del cuerpo cavernoso, mediante vasodilatación de las arterias helicinas del interior del pene. La vasodilatación incrementa el flujo de sangre en el interior del pene, causando así la erección. Robert F. Furchgott ganó el Premio Nobel de Fisiología y Medicina en 1998 por el descubrimiento y el análisis del factor de relajación derivado del endotelio (EDRF en siglas en inglés: endothelium-derived relaxing factor), que posteriormente fue identificado como óxido nítrico o algún otro compuesto relacionado muy cercano. Part of the physiological process of erection includes the parasympathetic nervous system causing the release of nitric oxide (NO) in the cavernous body of the penis. NO binds to the guanylate cyclase enzyme receptors, resulting in increased levels of cyclic guanosine monophosphate (cGMP), leading to a relaxation of the smooth muscle of the cavernous body, by vasodilation of the helicin arteries inside the penis. Vasodilation increases the flow of blood inside the penis, thus causing erection. Robert F. Furchgott won the Nobel Prize in Physiology and Medicine in 1998 for the discovery and analysis of the endothelium-derived relaxation factor (EDRF), which was subsequently identified as nitric oxide or some Another related compound very close.
Hay compuestos conocidos en el estado de técnica como el sildenafilo, cuyo mecanismo de acción consiste en la inhibición específica de la fosfodiesterasa tipo 5 (PDE5) que es responsable de la degradación del GMPc en el cuerpo cavernoso. La estructura molecular del sildenafilo es similar a la del GMPc compitiendo por la unión de éste a PDE5. El resultado es que el cGMP permanece más tiempo en el interior del pene, produciéndose erecciones más potentes y mantenidas. Los principios activos como el tadalafilo y el vardenafilo actúan siguiendo el mismo mecanismo. There are compounds known in the state of the art as sildenafil, whose mechanism of action consists in the specific inhibition of phosphodiesterase type 5 (PDE5) that is responsible for the degradation of cGMP in the corpora cavernosa. The molecular structure of sildenafil is similar to that of cGMP competing for its binding to PDE5. The result is that the cGMP remains longer inside the penis, producing more powerful and maintained erections. The active substances such as tadalafil and vardenafil act according to the same mechanism.
Pues bien, para evaluar biológicamente la efectividad de la composición de la presente invención tal y como se ha citado en el ejemplo 1 se han realizado estudios de actividad enzimática sobre la PDE5A aislado utilizando un método de detección de fluorescencia. Well, to biologically evaluate the effectiveness of the composition of the present invention as cited in example 1, enzymatic activity studies have been performed on the isolated PDE5A using a fluorescence detection method.
Para este ejemplo comparativo se utilizó el compuesto Zaprinast (inhibidor selectivo de PDE5A) para evaluar la For this comparative example the compound Zaprinast (selective PDE5A inhibitor) was used to evaluate the
actividad frente a la composición objeto de la presente invención (codificada como “Producto HT”). activity against the composition object of the present invention (encoded as "HT Product").
Se realizaron estudios de actividad (inhibición de PDE5A) frente a un control sin administración de agente activo de ambas composiciones a las siguientes concentraciones: Activity studies (PDE5A inhibition) were performed against a control without active agent administration of both compositions at the following concentrations:
- • •
- Zaprinast: 300 nM a 1000 nM Zaprinast: 300 nM to 1000 nM
- • •
- Producto HT: 0,16 µg/ml, 0,8 µg/ml, 4 µg/ml, 20 µg/ml, 100 µg/ml y 500 µg/ml. HT product: 0.16 µg / ml, 0.8 µg / ml, 4 µg / ml, 20 µg / ml, 100 µg / ml and 500 µg / ml.
Se valoró la actividad de inhibición enzimática de PDE5A y se observó que el porcentaje de inhibición de PDE5A con el The enzymatic inhibition activity of PDE5A was assessed and it was observed that the percentage of inhibition of PDE5A with the
Producto HT para aquellas concentraciones ≥ a 100 μg/ml oscila entre 44% y 77%, dando un resultado claramente HT product for those concentrations ≥ 100 μg / ml ranges between 44% and 77%, giving a clear result
positivo. Los valores obtenidos con la administración de Zaprinast para las concentraciones de 300 nM a 1000 nM fueron de 57% y 65% respectivamente. positive. The values obtained with the administration of Zaprinast for concentrations of 300 nM to 1000 nM were 57% and 65% respectively.
Por ello, en base a este estudio experimental, se observa que la composición objeto de la presente invención (también llamada Producto HT) es claramente eficaz frente a la disfunción eréctil. Therefore, based on this experimental study, it is observed that the composition object of the present invention (also called HT Product) is clearly effective against erectile dysfunction.
De forma importante la presente invención se refiere a una composición por vía oral para la mejora del bienestar sexual de personas de ambos sexos que comprende una cantidad efectiva de: Angelica sinensis, Cornus officinalis, Curcuma longa, Epimedium, Lycium barbarum, Punica granatum, Schisandra chinensis, Trigonella foenum-graecum, Tribulus terrestris, Rhodiola rosea, Eleutherococcus senticosus, Panax ginseng, Cuscuta sinensis, Arginina, Cafeína, Carbonato de magnesio, Taurina, Oxido de zinc, Vitamina B6 y Borato sódico. Importantly, the present invention relates to an oral composition for the improvement of sexual well-being of people of both sexes comprising an effective amount of: Angelica sinensis, Cornus officinalis, Curcuma longa, Epimedium, Lycium barbarum, Punica granatum, Schisandra chinensis, Trigonella foenum-graecum, Tribulus terrestris, Rhodiola rosea, Eleutherococcus senticosus, Panax ginseng, Cuscuta sinensis, Arginine, Caffeine, Magnesium carbonate, Taurine, Zinc oxide, Vitamin B6 and Sodium borate.
De forma preferida la composición se administra en forma de comprimido masticable. Preferably, the composition is administered as a chewable tablet.
La presente invención también se refiere al uso de la composición anteriormente citada para la preparación de un medicamento para el tratamiento de la disfunción eréctil y aumentar el bienestar sexual de hombres y mujeres sanos. The present invention also relates to the use of the aforementioned composition for the preparation of a medicament for the treatment of erectile dysfunction and to increase the sexual well-being of healthy men and women.
De forma preferida la composición de la presente invención se administra en forma de comprimido masticable. De forma preferida de 2500 mg. La presente invención también se refiere al uso de la composición anteriormente citada administrando dos comprimidos por vía oral al menos tres horas antes del acto sexual. Preferably, the composition of the present invention is administered as a chewable tablet. Preferably 2500 mg. The present invention also relates to the use of the aforementioned composition by administering two tablets orally at least three hours before sexual intercourse.
Claims (11)
- Ingredientes Ingredients
- miligramos milligrams
- Tribulus terrestris Tribulus Terrestris
- 250-750 mg 250-750 mg
- Arginina Arginine
- 125- 1000 mg 125-1000 mg
- Taurina Taurine
- 125- 1000 mg 125-1000 mg
- Trigonella foenum-graecum Trigonella foenum-graecum
- 75-300 mg 75-300 mg
- Epimedium Epimedium
- 75-205 mg 75-205 mg
- Carbonato de magnesio Magnesium carbonate
- 100- 200 mg 100-200 mg
- Schisandra sinensis Schisandra sinensis
- 50- 150 mg 50-150 mg
- Angelica sinensis Angelica sinensis
- 50-100 mg 50-100 mg
- Lycium barbarum Lycium barbarum
- 30-500 mg 30-500 mg
- Cuscuta sinensisCuscuta sinensis
- 25-200 mg 25-200 mg
- Punica granatum Punica granatum
- 25-500 mg 25-500 mg
- Rhodiola rosea Rhodiola rosea
- 25-500 mg 25-500 mg
- Eleutherococcus senticosus Eleutherococcus senticosus
- 25-500 mg 25-500 mg
- Panax ginseng Panax ginseng
- 25-500 mg 25-500 mg
- Borato sódico Sodium borate
- 25-50 mg 25-50 mg
- Curcuma longa Curcuma longa
- 20-100 mg 20-100 mg
- Cornus officinalis Cornus officinalis
- 10-40 mg 10-40 mg
- Cafeína Caffeine
- 10-300mg 10-300mg
- Oxido de zinc Zinc oxide
- 5-13 mg 5-13 mg
- Vitamina B6-piridoxina Vitamin B6-Pyridoxine
- 3-6 mg 3-6 mg
- Ingredientes Ingredients
- miligramos milligrams
- Tribulus terrestris Tribulus Terrestris
- 500 mg 500 mg
- Arginina Arginine
- 250,00 mg 250.00 mg
- Taurina Taurine
- 250,00 mg 250.00 mg
- Trigonella foenum-graecum Trigonella foenum-graecum
- 150,00 mg 150.00 mg
- Epimedium Epimedium
- 125,00 mg 125.00 mg
- Carbonato de magnesio Magnesium carbonate
- 125,00 mg 125.00 mg
- Schisandra sinensis Schisandra sinensis
- 100,00 mg 100.00 mg
- Angelica sinensis Angelica sinensis
- 75,00 mg 75.00 mg
- Lycium barbarum Lycium barbarum
- 60,00 mg 60.00 mg
- Cuscuta sinensis Cuscuta sinensis
- 50,00 mg 50.00 mg
- Punica granatum Punica granatum
- 50,00 mg 50.00 mg
- Rhodiola rosea Rhodiola rosea
- 50,00 mg 50.00 mg
- Eleutherococcus senticosus Eleutherococcus senticosus
- 50,00 mg 50.00 mg
- Panax ginseng Panax ginseng
- 50,00 mg 50.00 mg
- Borato sódico Sodium borate
- 44,10 mg 44.10 mg
- Curcuma longa Curcuma longa
- 32,50 mg 32.50 mg
- Cornus officinalis Cornus officinalis
- 20,00 mg 20.00 mg
- Cafeína Caffeine
- 15,00 mg 15.00 mg
- Oxido de zinc Zinc oxide
- 6,25 mg 6.25 mg
- Vitamina B6-piridoxina Vitamin B6-Pyridoxine
- 3,00 mg 3.00 mg
- Excipientes Excipients
- 491,15 mg 491.15 mg
- Categoría Category
- 56 Documentos citados Reivindicaciones afectadas 56 Documents cited Claims Affected
- A TO
- US 2009175936 A1 (RÖHR, W.) 09.07.2009, página 2, [0028]-[0030],[0032]. 1-4 US 2009175936 A1 (RÖHR, W.) 09.07.2009, page 2, [0028] - [0030], [0032]. 1-4
- A TO
- JP 2004305089 A (TAISHO PHARM CO LTD) 04.11.2004 & Resumen de base de datos WPI. Recuperado de EPOQUE; Número de acceso 2004-778402. 1-4 JP 2004305089 A (TAISHO PHARM CO LTD) 04.11.2004 & WPI database summary. Recovered from EPOQUE; Accession number 2004-778402. 1-4
- A TO
- US 2008026082 A1 (OLALDE RANGEL, J. A.) 31.01.2008, página 2, [0015],[0017]; página 4, [0023]; páginas 5-6, Ejemplo 2, Tabla 1. 1,4-7 US 2008026082 A1 (OLALDE RANGEL, J. A.) 31.01.2008, page 2, [0015], [0017]; page 4, [0023]; pages 5-6, Example 2, Table 1. 1.4-7
- A TO
- WO 2009045505 A2 (LIBIDINOL LLC) 09.04.2009, página 3; página 4, líneas 23-29; página 5; páginas 10-12, Ejemplos 1,2; página 13, líneas 8-14; página 14, líneas 1-10; página 15, línea 22 – página 16, línea 25. 1-4 WO 2009045505 A2 (LIBIDINOL LLC) 04.04.2009, page 3; page 4, lines 23-29; page 5; pages 10-12, Examples 1,2; page 13, lines 8-14; page 14, lines 1-10; page 15, line 22 - page 16, line 25. 1-4
- A TO
- CN 101317940 A (YUEJIN WANG) 10.12.2008 & Resumen de base de datos EPODOC. Recuperado de EPOQUE; Número de acceso CN-200810140557-A. 1,4-7 CN 101317940 A (YUEJIN WANG) 10.12.2008 & EPODOC database summary. Recovered from EPOQUE; Accession number CN-200810140557-A. 1.4-7
- A TO
- CN 102949521 A (XI AN TAIKOMED MEDICAL TECHNOLOGY CO LTD) 06.03.2013 & Resumen de base de datos EPODOC. Recuperado de EPOQUE; Número de acceso CN-201210481208-A. 1,4-7 CN 102949521 A (XI AN TAIKOMED MEDICAL TECHNOLOGY CO LTD) 06.03.2013 & EPODOC database summary. Recovered from EPOQUE; Accession number CN-201210481208-A. 1.4-7
- A TO
- LOW, W. Y; TAN, H. M. Asian traditional medicine for erectile dysfunction. The Journal of Men's Health & Gender, 2007. Vol. 4, nº 3, páginas 245-250. ISSN 1571-8913. Doi:10.1016/j.jmhg.2007.05.010 1,4-7 LOW, W. Y; TAN, H. M. Asian traditional medicine for erectile dysfunction. The Journal of Men's Health & Gender, 2007. Vol. 4, No. 3, pages 245-250. ISSN 1571-8913. Doi: 10.1016 / j.jmhg. 2007.05.010 1.4-7
- A TO
- WO 2006021930 A2 (FEMI-X A/S) 02.03.2006, página 4, [0019],[0020]; página 5, [0024]. 1,4-7 WO 2006021930 A2 (FEMI-X A / S) 02.03.2006, page 4, [0019], [0020]; page 5, [0024]. 1.4-7
- A TO
- ES 2386859 B1 (GOMEZ DE DIEGO, E. A.) 22.03.2013, páginas 2,4. 1,4-7 EN 2386859 B1 (GOMEZ DE DIEGO, E. A.) 03.23.2013, pages 2.4. 1.4-7
- Categoría de los documentos citados X: de particular relevancia Y: de particular relevancia combinado con otro/s de la misma categoría A: refleja el estado de la técnica O: referido a divulgación no escrita P: publicado entre la fecha de prioridad y la de presentación de la solicitud E: documento anterior, pero publicado después de la fecha de presentación de la solicitud Category of the documents cited X: of particular relevance Y: of particular relevance combined with other / s of the same category A: reflects the state of the art O: refers to unwritten disclosure P: published between the priority date and the date of priority submission of the application E: previous document, but published after the date of submission of the application
- El presente informe ha sido realizado • para todas las reivindicaciones • para las reivindicaciones nº: This report has been prepared • for all claims • for claims no:
- Fecha de realización del informe 14.05.2014 Date of realization of the report 14.05.2014
- Examinador A. Sukhwani Página 1/4 Examiner A. Sukhwani Page 1/4
- Documento Document
- Número Publicación o Identificación Fecha Publicación Publication or Identification Number publication date
- D01 D01
- US 2009175936 A1 (RÖHR, W.) 09.07.2009 US 2009175936 A1 (RÖHR, W.) 07.07.2009
- D02 D02
- JP 2004305089 A (TAISHO PHARM CO LTD) 04.11.2004 JP 2004305089 A (TAISHO PHARM CO LTD) 04.11.2004
- D03 D03
- US 2008026082 A1 (OLALDE RANGEL, J. A.) 31.01.2008 US 2008026082 A1 (OLALDE RANGEL, J. A.) 01.31.2008
- D04 D04
- WO 2009045505 A2 (LIBIDINOL LLC) 09.04.2009 WO 2009045505 A2 (LIBIDINOL LLC) 04.09.2009
- D05 D05
- CN 101317940 A (YUEJIN WANG) 10.12.2008 CN 101317940 A (YUEJIN WANG) 10.12.2008
- D06 D06
- CN 102949521 A (XI AN TAIKOMED MEDICAL TECHNOLOGY CO LTD) 06.03.2013 CN 102949521 A (XI AN TAIKOMED MEDICAL TECHNOLOGY CO LTD) 06.03.2013
- D07 D07
- LOW, W. Y; TAN, H. M. Asian traditional medicine for erectile dysfunction. The Journal of Men's Health & Gender, 2007. Vol. 4, nº 3, páginas 245-250. 2007 LOW, W. Y; TAN, H. M. Asian traditional medicine for erectile dysfunction. The Journal of Men's Health & Gender, 2007. Vol. 4, No. 3, pages 245-250. 2007
- D08 D08
- WO 2006021930 A2 (FEMI-X A/S) 02.03.2006 WO 2006021930 A2 (FEMI-X A / S) 02.03.2006
- D09 D09
- ES 2386859 B1 (GOMEZ DE DIEGO, E. A.) 22.03.2013 ES 2386859 B1 (GOMEZ DE DIEGO, E. A.) 03/22/2013
- --
- D01 se refiere a preparaciones farmacéuticas que comprenden vitaminas como la B6 piridoxina (página 2, [0028]), minerales como el boro, magnesio y zinc (página 2, [0029]), aminoácidos como la L-arginina (página 2, [0030]), y extractos de plantas enumerando más de cien, y entre ellas 11 de las reivindicadas como Angelica sinensis, Curcuma longa (turmeric), Epimedium, Lycium barbarum (wolfberry), Punica granatum (pomegranate), Schisandra chinensis, Trigonella foenum-graecum (fenufreek), Tribulus terrestris, Rhodiola rosea, Eleutherococcus senticosus, Panax ginseng, (página 2, [0032]), citando dieciséis de los veinte componentes, sin especificar si están todos en la misma composición por lo que no anticipa la invención. D01 refers to pharmaceutical preparations comprising vitamins such as B6 pyridoxine (page 2, [0028]), minerals such as boron, magnesium and zinc (page 2, [0029]), amino acids such as L-arginine (page 2, [ 0030]), and plant extracts listing more than one hundred, and among them 11 of those claimed as Angelica sinensis, Curcuma longa (turmeric), Epimedium, Lycium barbarum (wolfberry), Punica granatum (pomegranate), Schisandra chinensis, Trigonella foenum- graecum (fenufreek), Tribulus terrestris, Rhodiola rosea, Eleutherococcus senticosus, Panax ginseng, (page 2, [0032]), citing sixteen of the twenty components, without specifying whether they are all in the same composition and therefore do not anticipate the invention.
- --
- D02 divulga en una bebida siete plantas, entre ellas la Cuscuta y el Cornus officinalis junto con Angelica, Schisandra, ginseng, Epimedium, Eleutherococcus, además de cafeína y taurina (resumen) pero no todos los componentes reivindicados.D02 discloses in a drink seven plants, including Cuscuta and Cornus officinalis along with Angelica, Schisandra, ginseng, Epimedium, Eleutherococcus, as well as caffeine and taurine (summary) but not all of the claimed components.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201430039A ES2462553B2 (en) | 2014-01-16 | 2014-01-16 | Composition to improve sexual well-being |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201430039A ES2462553B2 (en) | 2014-01-16 | 2014-01-16 | Composition to improve sexual well-being |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2462553A1 true ES2462553A1 (en) | 2014-05-23 |
| ES2462553B2 ES2462553B2 (en) | 2014-11-05 |
Family
ID=50732646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES201430039A Active ES2462553B2 (en) | 2014-01-16 | 2014-01-16 | Composition to improve sexual well-being |
Country Status (1)
| Country | Link |
|---|---|
| ES (1) | ES2462553B2 (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104887809A (en) * | 2015-06-15 | 2015-09-09 | 平阴县中医医院 | Medicine for treating gynecologic inflammation and preparation method thereof |
| CN104906229A (en) * | 2015-06-08 | 2015-09-16 | 山东大学齐鲁医院 | Traditional Chinese medicine gel preparation for treating cervicitis |
| CN107890473A (en) * | 2017-11-27 | 2018-04-10 | 中国科学院兰州化学物理研究所 | A kind of composition with fatigue-relieving and Yang strengthening function |
| CN108653644A (en) * | 2018-07-20 | 2018-10-16 | 成都润馨堂药业有限公司 | A kind of pharmaceutical composition of warming kidney and enhancing yang and its preparation method and application |
| EP3610882A1 (en) * | 2018-06-11 | 2020-02-19 | Mohammad S. Majid | Herbal combination product |
| WO2020068964A3 (en) * | 2018-09-26 | 2020-04-30 | Aretha Duncan | Synergistic herbal stimulant compositions |
| WO2022175981A1 (en) * | 2021-02-18 | 2022-08-25 | Sipwise Beverages Pvt. Ltd | A synergistic herbal composition for improving sexual wellness in females |
| WO2022175980A1 (en) * | 2021-02-18 | 2022-08-25 | Sipwise Beverages Pvt. Ltd | A synergistic herbal composition for improving male sexual wellness |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004305089A (en) * | 2003-04-07 | 2004-11-04 | Taisho Pharmaceut Co Ltd | Drink composition |
| WO2006021930A2 (en) * | 2004-08-25 | 2006-03-02 | Femi-X A/S | Aphrodisiac herbal composition for a female comprising epimedium grandiflorum, turnera diffusa var. aphrodisiaca, ilex paraguariensis and smilax spp |
| US20080026082A1 (en) * | 2006-07-28 | 2008-01-31 | Jose Angel Olalde Rangel | Erectyle disfunction phyto-nutraceutical synergistic composition |
| CN101317940A (en) * | 2008-07-14 | 2008-12-10 | 王跃进 | Traditional Chinese medicine capsule for increasing spermatozoon |
| WO2009045505A2 (en) * | 2007-10-03 | 2009-04-09 | Libidinol Llc | Prohormone composition and method of use thereof |
| US20090175936A1 (en) * | 2006-02-10 | 2009-07-09 | Biogenerics Pharma Gmbh | Microtablet-Based Pharmaceutical Preparation |
| CN102949521A (en) * | 2012-11-23 | 2013-03-06 | 西安泰科迈医药科技有限公司 | Pure traditional Chinese medicinal health care product used for relieving physical fatigue and preparation method thereof |
| ES2386859B1 (en) * | 2011-02-07 | 2013-03-22 | Eduardo Antonio Gómez De Diego | NATURAL COMPOSITION TO INCREASE VIGOR. |
-
2014
- 2014-01-16 ES ES201430039A patent/ES2462553B2/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004305089A (en) * | 2003-04-07 | 2004-11-04 | Taisho Pharmaceut Co Ltd | Drink composition |
| WO2006021930A2 (en) * | 2004-08-25 | 2006-03-02 | Femi-X A/S | Aphrodisiac herbal composition for a female comprising epimedium grandiflorum, turnera diffusa var. aphrodisiaca, ilex paraguariensis and smilax spp |
| US20090175936A1 (en) * | 2006-02-10 | 2009-07-09 | Biogenerics Pharma Gmbh | Microtablet-Based Pharmaceutical Preparation |
| US20080026082A1 (en) * | 2006-07-28 | 2008-01-31 | Jose Angel Olalde Rangel | Erectyle disfunction phyto-nutraceutical synergistic composition |
| WO2009045505A2 (en) * | 2007-10-03 | 2009-04-09 | Libidinol Llc | Prohormone composition and method of use thereof |
| CN101317940A (en) * | 2008-07-14 | 2008-12-10 | 王跃进 | Traditional Chinese medicine capsule for increasing spermatozoon |
| ES2386859B1 (en) * | 2011-02-07 | 2013-03-22 | Eduardo Antonio Gómez De Diego | NATURAL COMPOSITION TO INCREASE VIGOR. |
| CN102949521A (en) * | 2012-11-23 | 2013-03-06 | 西安泰科迈医药科技有限公司 | Pure traditional Chinese medicinal health care product used for relieving physical fatigue and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| LOW, W. Y; TAN, H. M. Asian traditional medicine for erectile dysfunction. The Journal of Men's Health & Gender, 2007. * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104906229A (en) * | 2015-06-08 | 2015-09-16 | 山东大学齐鲁医院 | Traditional Chinese medicine gel preparation for treating cervicitis |
| CN104887809A (en) * | 2015-06-15 | 2015-09-09 | 平阴县中医医院 | Medicine for treating gynecologic inflammation and preparation method thereof |
| CN107890473A (en) * | 2017-11-27 | 2018-04-10 | 中国科学院兰州化学物理研究所 | A kind of composition with fatigue-relieving and Yang strengthening function |
| EP3610882A1 (en) * | 2018-06-11 | 2020-02-19 | Mohammad S. Majid | Herbal combination product |
| CN108653644A (en) * | 2018-07-20 | 2018-10-16 | 成都润馨堂药业有限公司 | A kind of pharmaceutical composition of warming kidney and enhancing yang and its preparation method and application |
| WO2020068964A3 (en) * | 2018-09-26 | 2020-04-30 | Aretha Duncan | Synergistic herbal stimulant compositions |
| WO2022175981A1 (en) * | 2021-02-18 | 2022-08-25 | Sipwise Beverages Pvt. Ltd | A synergistic herbal composition for improving sexual wellness in females |
| WO2022175980A1 (en) * | 2021-02-18 | 2022-08-25 | Sipwise Beverages Pvt. Ltd | A synergistic herbal composition for improving male sexual wellness |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2462553B2 (en) | 2014-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2462553A1 (en) | Composition for improvement of sexual well-being (Machine-translation by Google Translate, not legally binding) | |
| ES2710126T3 (en) | Full leech saliva extract | |
| ES2259139T3 (en) | USEFUL FORMULATIONS IN THE TREATMENT OF MALE AND FEMALE IMPOTENCE. | |
| US6338862B1 (en) | Composition and method of use in treating sexual dysfunction using cGMP-specific phosphodiesterase type 5 inhibitors | |
| ES2259144T3 (en) | USEFUL FORMULATIONS IN THE TREATMENT OF MALE AND FEMALE IMPOTENCE. | |
| KR101975729B1 (en) | Compositions and methods for treating erectile dysfunction | |
| ES2804324T3 (en) | Compositions containing extracts of Curcuma longa and Echinacea angustifolia that are useful for reducing peripheral inflammation and pain | |
| CN107614061A (en) | For treating the antimigraine and illness method and composition relevant with pain | |
| ES2405323T3 (en) | Melanoma treatment | |
| ES2330795T3 (en) | COMBINATIONS OF VASOACTIVE AGENTS AND THEIR USE IN THE TREATMENT OF SEXUAL DYSFUNCTIONS. | |
| EA038052B1 (en) | Combination comprising palmitoylethanolamide for treating chronic pain | |
| RU2180591C2 (en) | Agent for treatment of men with sexual disorders | |
| US20170333475A1 (en) | Food Supplement for Restoring Male Sex Drive (Libido) | |
| EP3750532A1 (en) | A food supplement for use in restoring male sex drive (libido) | |
| SI2694065T1 (en) | Composition for treating hypoactive sexual desire disorder | |
| CN107569496A (en) | Antineoplastic pharmaceutical compositions and its application comprising salicylic acid compounds and alcohol-based liquid curing agent | |
| TW200626133A (en) | Oral medication for twice-daily administration | |
| ES2587932T3 (en) | Compositions for use in relieving symptoms associated with premenstrual syndrome and premenstrual dysphoric disorder | |
| RU2421211C2 (en) | Agent for male sexual dysfunction correction | |
| IT201800003814A1 (en) | FORMULATION BASED ON COFFEE POWDER | |
| KR20040026277A (en) | The health-supporting food being effective the sexual energy strength and its preparat ion method | |
| WO2011041920A2 (en) | Nutraceutical composition that comprises extract of shilajit, folic acid, vitamin b12 and vitamin b6 and the use thereof for preventing and/or treating neurodegenerative diseases and/or the cognitive deterioration associated with cerebral ageing | |
| ES2917975T3 (en) | Food supplements for use in the prophylaxis and treatment of migraine | |
| CA2880753C (en) | A3 adenosine receptor ligands for use in treatment of a sexual dysfunction | |
| CN111093670A (en) | Tertiary-based supplements and methods of use thereof in synergistic combinations with caffeine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 2462553 Country of ref document: ES Kind code of ref document: B2 Effective date: 20141105 |